SEC Tracker
Get the app

Annovis Bio ANVS

Annovis Bio FY 2023: revenue $0; diluted EPS −$6.23

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.6
Material contract

Key figures from this report

These are the numbers Annovis Bio reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$0Against $0 in FY 202210-K income statement, on EDGAR
  2. Net income−$56.2MAgainst −$25.3M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$6.23Against −$3.10 in FY 202210-K income statement, on EDGAR
  4. Cash and cash equivalents$5.8M−80% from $28.4M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$40.0MAgainst −$17.3M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Annovis Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  2. Karyopharm Therapeutics KPTI public float $37M, Jun 30, 2025
  3. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  4. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
  5. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025